ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Purpose
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Early Stage Breast Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients (females and males) with clinical stage T1c-T3 (or Tx) and nodal stage N0-N1 (except T3N1 tumors, which are not eligible) - Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Patients with residual isolated tumor cells at surgery are considered node-positive and are not eligible - HER2+ by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Central pathology review is not required. In cases where there were multiple tumor sites in breast/nodes that had HER2 testing at diagnosis, at least one site must have been HER2+ AND the treating investigator must feel it is in the patient's best interest to be treated as having HER2+ breast cancer - Known hormone receptor status as defined by ASCO/CAP guidelines. Estrogen receptor (ER) and progesterone receptor (PR) of any values are allowed. Hormone receptor positive status can be determined by either known positive ER or known positive PR status; hormone receptor negative status must be determined by both known negative ER and known negative PR - If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts (including the requirement that at least one biopsied site on each side must have been HER2+) - Age ≥ 18 years - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Patients must have received neoadjuvant chemotherapy in combination with trastuzumab with or without pertuzumab for a minimum of 12 weeks. All chemotherapy must have been completed preoperatively - Patient must complete a minimum of 12 weeks of coverage with trastuzumab and a maximum of 24 weeks in the combined neoadjuvant and adjuvant setting prior to trial registration. Trastuzumab may have been administered either weekly or once every 3 weeks (q3weeks). (For purposes of this eligibility criterion, a single dose of q3week trastuzumab would provide 3 weeks of coverage; a single dose of once a week (q1week) trastuzumab would provide 1 week of coverage. If a q3week dose of trastuzumab were administered and then the subsequent dose was delayed for any period of time, that would still count as 3 weeks of coverage.) - Administration of endocrine therapy for treatment of this breast cancer is allowed prior to trial registration. If a patient received prior breast cancer endocrine therapy (eg tamoxifen or aromatase inhibitor) for DCIS or preventive indication, and endocrine therapy is indicated for treatment of their current breast cancer, then prior endocrine therapy must have been stopped > 12 months prior to registration on this protocol - No use of investigational anti-cancer agents at time of registration - Patient must register within 14 weeks of final surgery - Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows: - Breast surgery: Total mastectomy with grossly negative margins (in the opinion of the surgeon there is no disease grossly at the margins) or breast-conserving surgery with histologically negative margins (no ink on tumor, including DCIS) unless those margins are anterior at the skin or posterior at the chest wall and no additional margin re-excision can be performed - Lymph node surgery: Lymph node surgery must have been performed and can include sentinel lymph node biopsy, targeted axillary dissection, or axillary dissection, at the discretion of the breast surgeon - Adequate radiation: Patients who completed breast-conserving surgery (i.e. lumpectomy) must have received or plan to receive adjuvant radiation. If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible. Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation) are not eligible - Adjuvant radiation can be given on study, and in this case is encouraged to be given concurrently with adjuvant HER2-directed therapy, per investigator discretion - Targeting of the regional nodal basins will be at treating investigator discretion - Not pregnant and not nursing, because this study involves agents with known teratogenic potential. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test should be performed prior to receiving HER2-directed therapy according to local standard practice - Adequate hepatic, renal and bone marrow function to receive adjuvant HER2-directed therapy in the opinion of the treating investigator. There are no specific required laboratory values for eligibility - No stage IV (metastatic) breast cancer - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - No history of any prior (ipsilateral [ipsi-] or contralateral) invasive breast cancer. Prior DCIS is allowed - No evidence of recurrent disease following preoperative therapy and surgery - Patients living with HIV who are healthy and deemed by their medical team to have a low risk of AIDS-related illnesses are included in this trial. Patients with Hepatitis B or Hepatitis C virus who are healthy and deemed by their medical team to meet all other enrollment criteria are included in this trial. - Patients with inadequate cardiac function on most recent assessment of left ventricular ejection fraction (LVEF) are not eligible for this trial. Inadequate cardiac function is defined as LVEF < 50% on echocardiogram (echo) or multiple-gated acquisition (MUGA) - No history of grade 3 or 4 toxicity related to trastuzumab. If pertuzumab is planned to be given on trial, patient must also have no history of grade 3-4 toxicity related to pertuzumab - No contraindication to receipt of further HER2-directed therapy - No patients with severe, uncontrolled systemic disease that may interfere with planned trial therapy.
Exclusion Criteria
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm 1 (12-month adjuvant therapy) |
Patients receive trastuzumab IV or SC on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial. |
|
|
Experimental Arm 2 (6-month adjuvant therapy) |
Patients receive trastuzumab IV or SC on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial. |
|
Recruiting Locations
Carmichael, California 95608
Carmichael, California 95608
Chico, California 95926
Site Public Contact
530-332-4700
Dublin, California 94568
Site Public Contact
877-642-4691
Elk Grove, California 95758
Fremont, California 94538
Fresno, California 93720
Site Public Contact
833-574-2273
Irvine, California 92612
La Jolla, California 92093
Marysville, California 95901
Site Public Contact
530-749-4400
Modesto, California 95356
Site Public Contact
877-642-4691
Modesto, California 95356
Oakland, California 94611
Orange, California 92868
Rocklin, California 95765
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95817
Site Public Contact
916-734-3089
Sacramento, California 95823
San Diego, California 92103
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Rafael, California 94903
Santa Clara, California 95051
Santa Rosa, California 95403
South San Francisco, California 94080
Truckee, California 96161
Site Public Contact
530-582-6450
Vallejo, California 94589
Walnut Creek, California 94596
Woodland, California 95695
Yorba Linda, California 92886
Edwards, Colorado 81632
Site Public Contact
970-569-7429
Derby, Connecticut 06418
Fairfield, Connecticut 06824
Glastonbury, Connecticut 06033
Greenwich, Connecticut 06830
Guilford, Connecticut 06437
Hartford, Connecticut 06105
New Haven, Connecticut 06520
North Haven, Connecticut 06473
Stamford, Connecticut 06902
Torrington, Connecticut 06790
Trumbull, Connecticut 06611
Waterbury, Connecticut 06708
Waterford, Connecticut 06385
Millville, Delaware 19967
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Washington D.C., District of Columbia 20007
Site Public Contact
202-444-2223
Washington D.C., District of Columbia 20010
Site Public Contact
202-877-8839
Clearwater, Florida 33756
Site Public Contact
855-314-8646
Jupiter, Florida 33458
Lakeland, Florida 33805
Site Public Contact
863-680-7780
Pensacola, Florida 32504
Plant City, Florida 33563
St. Petersburg, Florida 33705
Tampa, Florida 33607
Winter Haven, Florida 33881
Honolulu, Hawaii 96819
Boise, Idaho 83712
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83687
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Aurora, Illinois 60504
Bloomington, Illinois 61704
Canton, Illinois 61520
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60637
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
DeKalb, Illinois 60115
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Geneva, Illinois 60134
Glenview, Illinois 60026
Site Public Contact
312-695-1102
Grayslake, Illinois 60030
Site Public Contact
312-695-1102
Harvey, Illinois 60426
Hinsdale, Illinois 60521
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Macomb, Illinois 61455
Mattoon, Illinois 61938
Moline, Illinois 61265
Site Public Contact
309-779-2000
New Lenox, Illinois 60451
Normal, Illinois 61761
Normal, Illinois 61761
O'Fallon, Illinois 62269
Oak Brook, Illinois 60523
Orland Park, Illinois 60462
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Shiloh, Illinois 62269
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Warrenville, Illinois 60555
Washington, Illinois 61571
Yorkville, Illinois 60560
Avon, Indiana 46123
Carmel, Indiana 46032
Crown Point, Indiana 46307
Indianapolis, Indiana 46202
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Boone, Iowa 50036
Site Public Contact
515-956-4132
Carroll, Iowa 51401
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Clive, Iowa 50325
Site Public Contact
515-241-3305
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Fort Dodge, Iowa 50501
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Pella, Iowa 50219
Waukee, Iowa 50263
Site Public Contact
515-241-3305
West Des Moines, Iowa 50266
Site Public Contact
515-875-9815
Chanute, Kansas 66720
Dodge City, Kansas 67801
El Dorado, Kansas 67042
Independence, Kansas 67301
Kingman, Kansas 67068
Lawrence, Kansas 66044
Liberal, Kansas 67905
Newton, Kansas 67114
Olathe, Kansas 66061
Overland Park, Kansas 66210
Overland Park, Kansas 66211
Parsons, Kansas 67357
Pratt, Kansas 67124
Salina, Kansas 67401
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Wellington, Kansas 67152
Westwood, Kansas 66205
Wichita, Kansas 67208
Wichita, Kansas 67214
Wichita, Kansas 67214
Winfield, Kansas 67156
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Louisville, Kentucky 40245
New Orleans, Louisiana 70112
New Orleans, Louisiana 70121
Brewer, Maine 04412
Site Public Contact
800-987-3005
Brunswick, Maine 04011
Rockport, Maine 04856
Sanford, Maine 04073
Site Public Contact
207-459-1600
South Portland, Maine 04106
Aberdeen, Maryland 21001
Baltimore, Maryland 21201
Site Public Contact
800-888-8823
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Baltimore, Maryland 21237
Site Public Contact
443-777-7364
Baltimore, Maryland 21239
Bel Air, Maryland 21014
Site Public Contact
443-643-3010
Bel Air, Maryland 21015
Bethesda, Maryland 20889-5600
Site Public Contact
301-319-2100
Clinton, Maryland 20735
Site Public Contact
301-877-4673
Cumberland, Maryland 21502
Site Public Contact
240-964-1400
Glen Burnie, Maryland 21061
Site Public Contact
410-553-8100
Olney, Maryland 20832
Site Public Contact
855-546-1944
Ann Arbor, Michigan 48109
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48116
Site Public Contact
800-865-1125
Canton, Michigan 48188
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Escanaba, Michigan 49829
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Lansing, Michigan 48912
Livonia, Michigan 48154
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Wyoming, Michigan 49519
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Saint Cloud, Minnesota 56303
Sandstone, Minnesota 55072
Thief River Falls, Minnesota 56701
Site Public Contact
605-312-3320
Virginia, Minnesota 55792
Worthington, Minnesota 56187
Site Public Contact
605-312-3320
Ballwin, Missouri 63011
Site Public Contact
888-446-3729
Cape Girardeau, Missouri 63703
City of Saint Peters, Missouri 63376
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Kansas City, Missouri 64116
Site Public Contact
913-588-3671
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Osage Beach, Missouri 65065
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
St Louis, Missouri 63110
St Louis, Missouri 63129
St Louis, Missouri 63131
Site Public Contact
314-996-5569
St Louis, Missouri 63136
St Louis, Missouri 63141
Site Public Contact
314-251-7066
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Bellevue, Nebraska 68123
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68198
Lebanon, New Hampshire 03756
Cherry Hill, New Jersey 08002
Hackensack, New Jersey 07601
Site Public Contact
551-996-2897
Sewell, New Jersey 08080
Albuquerque, New Mexico 87106
Albuquerque, New Mexico 87110
Rio Rancho, New Mexico 87124
Buffalo, New York 14263
Stony Brook, New York 11794
Site Public Contact
800-862-2215
The Bronx, New York 10461
Chapel Hill, North Carolina 27599
Charlotte, North Carolina 28204
Hendersonville, North Carolina 28791
Huntersville, North Carolina 28078
Kernersville, North Carolina 27284
Matthews, North Carolina 28105
Mooresville, North Carolina 28117
Mount Airy, North Carolina 27030
Pinehurst, North Carolina 28374
Thomasville, North Carolina 27360
Wilmington, North Carolina 28401
Site Public Contact
910-342-3000
Winston-Salem, North Carolina 27103
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Canton, Ohio 44710
Centerville, Ohio 45459
Cincinnati, Ohio 45219
Columbus, Ohio 43210
Dayton, Ohio 45409
Dayton, Ohio 45415
Franklin, Ohio 45005-1066
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Troy, Ohio 45373
West Chester, Ohio 45069
Oklahoma City, Oklahoma 73104
Bend, Oregon 97701
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Hood River, Oregon 97031
Newberg, Oregon 97132
Oregon City, Oregon 97045
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Beaver, Pennsylvania 15009
Butler, Pennsylvania 16001
Chambersburg, Pennsylvania 17201
Site Public Contact
717-217-6020
Cranberry Township, Pennsylvania 16066
Ephrata, Pennsylvania 17522
Site Public Contact
717-721-4840
Erie, Pennsylvania 16505
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Farrell, Pennsylvania 16121
Gettysburg, Pennsylvania 17325
Site Public Contact
877-441-7957
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Harrisburg, Pennsylvania 17109
Indiana, Pennsylvania 15701
Jefferson Hills, Pennsylvania 15025
Johnstown, Pennsylvania 15901
Site Public Contact
814-534-4724
Lebanon, Pennsylvania 17042
McKeesport, Pennsylvania 15132
Site Public Contact
412-647-8073
Mechanicsburg, Pennsylvania 17050
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Monroeville, Pennsylvania 15146
N. Huntingdon, Pennsylvania 15642
New Castle, Pennsylvania 16105
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19114
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15213
Site Public Contact
412-647-2811
Pittsburgh, Pennsylvania 15215
Site Public Contact
412-784-4900
Pittsburgh, Pennsylvania 15237
Site Public Contact
412-367-6454
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
Seneca, Pennsylvania 16346
Site Public Contact
814-676-7900
Uniontown, Pennsylvania 15401
Washington, Pennsylvania 15301
West Mifflin, Pennsylvania 15122
Site Public Contact
412-653-8100
Wexford, Pennsylvania 15090
Williamsport, Pennsylvania 17754
Willow Grove, Pennsylvania 19090
York, Pennsylvania 17403
Site Public Contact
717-741-9229
York, Pennsylvania 17403
Site Public Contact
877-441-7957
Providence, Rhode Island 02903
Site Public Contact
401-444-1488
Westerly, Rhode Island 02891
Boiling Springs, South Carolina 29316
Easley, South Carolina 29640
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29615
Greer, South Carolina 29650
Seneca, South Carolina 29672
West Columbia, South Carolina 29169
Rapid City, South Dakota 57701
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Baytown, Texas 77521
Conroe, Texas 77384
Cypress, Texas 77429
Houston, Texas 77026-1967
Site Public Contact
713-566-5000
Houston, Texas 77030
Site Public Contact
713-790-2700
Houston, Texas 77030
Houston, Texas 77070
Houston, Texas 77079
Houston, Texas 77094
Site Public Contact
832-522-2873
League City, Texas 77573
Nassau Bay, Texas 77058
Sugar Land, Texas 77478
Sugar Land, Texas 77479
Site Public Contact
281-242-2873
The Woodlands, Texas 77385
Salt Lake City, Utah 84112
Saint Johnsbury, Vermont 05819
Lynchburg, Virginia 24501
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23226
Richmond, Virginia 23229
Richmond, Virginia 23235
Richmond, Virginia 23298
South Hill, Virginia 23970
Edmonds, Washington 98026
Issaquah, Washington 98029
Seattle, Washington 98122
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Huntington, West Virginia 25701
Morgantown, West Virginia 26506
Antigo, Wisconsin 54409
Ashland, Wisconsin 54806
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Madison, Wisconsin 53718
Madison, Wisconsin 53792
Medford, Wisconsin 54451
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Mukwonago, Wisconsin 53149
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oconto Falls, Wisconsin 54154
Rhinelander, Wisconsin 54501
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54481
Sturgeon Bay, Wisconsin 54235-1495
Waukesha, Wisconsin 53188
Site Public Contact
262-928-7632
Waukesha, Wisconsin 53188
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
Manatí, Puerto Rico 00674
Site Public Contact
787-621-4397
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- NCT ID
- NCT06876714
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
The primary and secondary objectives of the study: PRIMARY OBJECTIVES: I. To evaluate whether 6 months of combined neoadjuvant (neo)/adjuvant HER2 blockade results in a non-inferior recurrence-free survival (RFS) compared to 12 months of combined neo/adjuvant HER2 blockade, in patients with early stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade. II. To compare the Functional Assessment of Cancer Therapy-Breast (FACT-B) total score at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) SECONDARY OBJECTIVES: I. Secondary objectives are to evaluate whether 6 months compared to 12 months results in differences for the following: Ia. Grade 3 or higher adverse event (AE) rates; Ib. Overall survival (OS); Ic. Locoregional recurrence (LRR, both isolated LRR as first events, and LRR events simultaneous with distant metastasis [DM]) incidence; Id. RFS for key subgroups: baseline stage, hormone receptor (HR) status, neoadjuvant chemotherapy backbone, and dual versus single HER2 blockade in the adjuvant setting; Ie. Time to central nervous system (CNS) recurrence (both isolated CNS recurrence as first events, and CNS recurrence events simultaneous with distant metastasis and/or LRR). II. To compare the FACT-B total score at 18 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) III. To compare side effect bother as measured by the Functional Assessment of Cancer Therapy General Population 5 (FACT GP5) item at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) IV. To compare specific patient-reported symptomatic adverse events (i.e. diarrhea, constipation, fatigue, and rash) as measured by the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) QUALITY OF LIFE EXPLORATORY OBJECTIVES: I. To examine the different FACT-B subscales at all other evaluable time points. II. To examine heterogeneity of treatment effects within subgroups defined by subcutaneous versus intravenous treatment delivery. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive trastuzumab intravenously (IV) or subcutaneously (SC) on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography (ECHO) or multigated acquisition (MUGA) as well as mammography, ultrasound, or magnetic resonance imaging (MRI) throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial. ARM 2: Patients receive trastuzumab IV or SC on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial. After completion of study treatment, patients are followed up every 6 months for 5 years after registration or until recurrence and then annually for a total of 10 years after registration.